yf_tkr_ALNY · 2026-08-25 · Neutral AI sentiment
Alnylam Pharmaceuticals stock has fallen 46.8% over the past year, yet the valuation checks still flag it as leaning expensive rather than a clear bargain. With fresh clinical data on its RNAi programs coming at the ESC Congress 2026, investors are weighing that share price slump against what the current market valuation implies. The share price decline of 46.8% over the last 12 months signals that expectations have come down sharply and raises the question of whether sentiment has weakened...
Read the original at yf_tkr_ALNY ↗
Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.
Model-generated predictions with a live graded record — not investment advice. 模型生成的预测，非投资建议。